Indegene outlines AI strategy at analyst meet
By Abha Lohia · Editor ·
Indegene: revenue and funding and every story →
Bengaluru
- FY26 revenue was ₹35,105M with a 19.4% adjusted EBITDA margin and zero debt
- The company targets $2B+ revenue by expanding client tiers and capturing market share from agencies and CROs
- It serves 20 of the top 20 global pharma companies and has grown active clients from 44 to 91 in five years
What happened
- Indegene submitted a revised investor presentation to stock exchanges, correcting a duplicate page with no material change.
- For FY26, Indegene reported ₹35,105M in revenue and an adjusted EBITDA margin of 19.4%.
- The company has a zero debt balance sheet and a Net Revenue Retention above 100% every year.
- Revenue per employee as of March 2026 was $74.7K, and revenue per delivery employee was $86.5K.
- Indegene merged its indirect wholly owned subsidiaries Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting GmbH on September 9, 2026.
- The German merger involved no cash consideration or share exchange and had no material impact on the listed entity.
- Indegene will host Premji Invest for an in-person one-on-one meeting on September 11, 2026 in Bengaluru.
- The meeting with Premji Invest will not involve sharing any unpublished price-sensitive information.
Why it matters
- The global pharma industry is projected to grow from $1.4Tn to $2Tn+ by 2030, with a sector CAGR of 5%-7%.
- Indegene sees GenAI as a tailwind due to five structural reasons, including being a revenue partner and not a cost partner.
- The company has identified high-potential accounts with $150-200M potential as priority targets.
- Indegene's FY27 pipeline is 17% higher than the same point in the prior year.
The business
- Indegene is an AI-native life sciences operating partner, helping from clinical development to commercialization.
- It offers end-to-end solutions including Strategy & Consulting, Discovery & Development, Launch & Commercialization, and Technology & Operational Accelerators.
- The company is powered by Cortex, an intelligence layer connecting data, workflows, human expertise, and AI.
- Indegene serves 20 of the top 20 and 80 of the top 100 global life sciences companies.
- It has been purpose-built for life sciences for 27+ years and claims 20-30% faster decision cycles.
- Revenue per employee as of March 2026 was $74.7K, and revenue per delivery employee was $86.5K.
- The company has grown active client relationships from 44 in FY21 to 91 in FY26 (2.0x).
- Clients with $1M+ revenue grew from 22 in FY21 to 53 in FY26 (2.4x).
In numbers
₹35,105MFY26 revenue · 2026
19.4%FY26 adjusted EBITDA margin · 2026
29.4%Revenue CAGR FY21-FY26 (INR) · 2026
above 100% every yearNet Revenue Retention · 2026
162%OCF to PAT ratio · 2026
$74.7KRevenue per employee · 2026
$86.5KRevenue per delivery employee · 2026
16.7%PAT CAGR FY21-FY26 · 2026
24.9%Top-20 client revenue CAGR FY21-FY26 · 2026
91Active client relationships · 2026
53Clients with $1M+ revenue · 2026
₹25.2k MnTop-20 revenue · 2026
51%Top 10 clients share of revenue · 2026
€20,100,000Projected revenue for Indegene Healthcare Germany GmbH FY26-27 · 2027
What happens next
- Indegene targets a multi-billion dollar growth roadmap by expanding client tiers and capturing market share from agencies and CROs through AI-driven centralization.
- The mid-term plan includes growing Tier 1 (strategic >$25M) clients from 3 to 9, with one crossing $100M.
- It plans to grow Tier 2 ($10-25M) clients from 7 to 16 with 2x account growth.
- The company aims for 50% growth in mid-size pharma in Tier 3 ($1-10M) and 1.5x growth in Tier 4 ($0.25-1M) account count.
- Strategic priorities include traction in new solutions Tectonic and Medical Writing, M&A capability expansion via acquisitions of Cult, Trilogy, Biopharm, Warn, Cake Communications, and continued AI platform investment.
- Indegene's current scale is approximately $400M, with a near-term target of $500M+.
- The company has a stated $2B+ vision supported by consulting-led selling and a high-talent team.
Words to know
- EBITDA
- Earnings Before Interest, Taxes, Depreciation, and Amortisation – a measure of a company's operating profitability.
- CAGR
- Compound Annual Growth Rate – the average annual growth rate over a specified period.
- OCF to PAT ratio
- Operating Cash Flow to Profit After Tax ratio – indicates how much cash a company generates relative to its reported profit.
- Net Revenue Retention
- A metric that measures the revenue retained from existing clients over a period, including upsells and cross-sells, minus churn.
The numbers around it
Healthcare & Life Sciences in September 2026: 11 rounds with a disclosed amount, $114 million in all; the biggest was Ultrahuman ($70 mn). Every sector this year →
Terms in this story
- EBITDA: EBITDA is earnings before interest, tax, depreciation and amortisation, a measure of operating profit before financing and accounting charges. It is not the same as net profit. In Indian startup results, check whether EBITDA includes ESOP costs, since adjusted versions often leave them out.
- Financial year: An Indian financial year runs from 1 April to 31 March, and it is named after the year it ends. FY26 means April 2025 to March 2026. Startup results for a year arrive months after it closes, so a November 2026 story may still be about FY25.
- Profitability: Profitable can mean five different things in a startup headline: profit after tax, positive EBITDA, positive adjusted EBITDA, positive cash flow or profit on each order. Only the first is a profit in the full accounting sense. Always check which one a story means.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
Everything on Indegene → · All startup news on 10 September 2026 →
Is this Indegene? Get your “Featured on StopDown” badge →